The role of the Fc‐mediated effector functions in cancer therapy using PD‐L1 blocking antibodies has been discussed controversially (Cohen Saban et al., 2023; Knorr and Ravetch, 2019; Leitner et al., 2021; Yu et al., 2020). Here, CD274 is linked to cancer.